Evidence map›Paper›PMID 27347659›Full record

ArticleInternational journal of cancer2016

A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants.

Amaury Vaysse, Shenying Fang, Myriam Brossard, Qingyi Wei, Wei V Chen, Hamida Mohamdi, Lynda Vincent-Fetita, Patricia Margaritte-Jeannin, Nolwenn Lavielle, Eve Maubec and 5 more

Open access · greenAbstract read
In one paragraph

Article in International journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Avicenna journal of medical biotechnology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Host Characteristics and Risk of Incident Melanoma by Breslow Thickness.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 3 countries.

Amaury VaysseINSERM, Genetic Variation and Human Diseases Unit, UMR-946, Paris, France.
Shenying FangDepartment of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.
Myriam BrossardINSERM, Genetic Variation and Human Diseases Unit, UMR-946, Paris, France.
Qingyi WeiDuke Cancer Institute, Duke University Medical Center and Department of Medicine, Duke University School of Medicine, Durham, NC.
Wei V ChenLaboratory Informatics System, Department of Clinical Applications & Support, the University of Texas M. D. Anderson Cancer Center, Houston, TX.
Hamida MohamdiINSERM, Genetic Variation and Human Diseases Unit, UMR-946, Paris, France.
Lynda Vincent-FetitaAP-HP, Hôpital Cochin Et Université Paris Descartes, Paris, France.
Patricia Margaritte-JeanninINSERM, Genetic Variation and Human Diseases Unit, UMR-946, Paris, France.
Nolwenn LavielleINSERM, Genetic Variation and Human Diseases Unit, UMR-946, Paris, France.
Eve MaubecINSERM, Genetic Variation and Human Diseases Unit, UMR-946, Paris, France.
Mark LathropMcGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
Marie-Françoise AvrilAP-HP, Hôpital Cochin Et Université Paris Descartes, Paris, France.
Christopher I AmosDepartment of Community and Family Medicine, Geisel College of Medicine, Dartmouth College, Hanover, NH.
Jeffrey E LeeDepartment of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.
Florence DemenaisINSERM, Genetic Variation and Human Diseases Unit, UMR-946, Paris, France.
The University of Texas MD Anderson Cancer Center · USUniversité Paris Cité · FRHuman Genetic of Infectious Diseases · FRDartmouth College · USDélégation Paris 7 · FRDuke Medical Center · USHôpital Avicenne · FRHôpital Cochin · FRInserm · FRMcGill University and Génome Québec Innovation Centre · CA

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7M
Genetic Epidermiology of MelanomaR01CA083115 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BISHOP, DAVID TIMOTHY, ELDER, DAVID ERIC · 2001 to 2017
$13.0M
Genetic Predictors for DNA Repair Phenotype in CMMR01CA100264 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WEI, QINGYI · 2004 to 2008
$1.5M
Statistical Methods for Gene Environment Interactions In Lung CancerR01CA133996 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMOS, CHRISTOPHER I. · 2007 to 2009
$790k
NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023108NCI NIH HHS P50 CA093459NCI NIH HHS R01 CA100264NCI NIH HHS R01 CA133996
6 · The paper itself

Abstract

Breslow thickness (BT) is a major prognostic factor of cutaneous melanoma (CM), the most fatal skin cancer. The genetic component of BT has only been explored by candidate gene studies with inconsistent results. Our objective was to uncover the genetic factors underlying BT using an hypothesis-free genome-wide approach. Our analysis strategy integrated a genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) for BT followed by pathway analysis of GWAS outcomes using the gene-set enrichment analysis (GSEA) method and epistasis analysis within BT-associated pathways. This strategy was applied to two large CM datasets with Hapmap3-imputed SNP data: the French MELARISK study for discovery (966 cases) and the MD Anderson Cancer Center study (1,546 cases) for replication. While no marginal effect of individual SNPs was revealed through GWAS, three pathways, defined by gene ontology (GO) categories were significantly enriched in genes associated with BT (false discovery rate ≤5% in both studies): hormone activity, cytokine activity and myeloid cell differentiation. Epistasis analysis, within each significant GO, identified a statistically significant interaction between CDC42 and SCIN SNPs (pmeta-int =2.2 × 10(-6) , which met the overall multiple-testing corrected threshold of 2.5 × 10(-6) ). These two SNPs (and proxies) are strongly associated with CDC42 and SCIN gene expression levels and map to regulatory elements in skin cells. This interaction has important biological relevance since CDC42 and SCIN proteins have opposite effects in actin cytoskeleton organization and dynamics, a key mechanism underlying melanoma cell migration and invasion.

Indexed as

Polymorphism, Single NucleotideAdultcdc42 GTP-Binding ProteinCutaneous Malignant MelanomaDatabases, GeneticEpistasis, GeneticFemaleGelsolinGene OntologyGenome-Wide Association StudyHumansMaleMelanomaMiddle AgedSkin Neoplasmscdc42 GTP-Binding ProteinGelsolinscinderinBreslow thicknessgene-gene interactiongenome-wide association studiesmelanomapathway analysis

Identifiers

PMID27347659
PMCPMC5116391
OpenAlexW2461652168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.